In this episode, we discuss recent news of trial coronavirus vaccines in development by companies such as AstraZeneca and Pfizer. Today, the U.S. government as part of its "Operation Warpspeed" struck a deal with Pfizer to purchase 100 million doses of the trial vaccine. The deal registered at $1.5 billion. This news spurred some market confidence on Wall Street and is quelling fears that the pandemic may be drawn out for over another year. The vaccines still must pass regulatory requirements by the FDA in order to be deemed safe. As it relates to the political implications, President Trump would surely benefit from a coronavirus vaccine and convince the American people that there will be an economic recovery. If there is a lack of a vaccine or preventative measure by election day, his opponent Joe Biden can capitalize on his handling of the pandemic. It remains to be seen how the President's handling will affect the electoral outcome.

*Correction: There has been no president in American history to have lost the popular vote twice while winning the electoral college.